enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA clears Tyler company’s device to treat obstructive sleep ...

   www.aol.com/fda-approves-tyler-company-device...

   The AIO Breathe Device is a “new mandibular repositioning device” that was designed by local sleep physician Dr. Raghavendra V. Ghuge, MD, MBA, DABSM, […] FDA clears Tyler company’s device ...

3. Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U ...

   lite.aol.com/tech/story/0022/20240902/1000989628.htm

   Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device . FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end of 2024. U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raised

4. US FDA clears Vivos Therapeutics' oral device for sleep apnea

   www.aol.com/news/us-fda-clears-vivos...

   OSA is the most common sleep-related breathing disorder, which occurs when throat muscles intermittently relax and block the airway during sleep. US FDA clears Vivos Therapeutics' oral device for ...

5. Sleep Apnea Device Maker ResMed Is A Durable MedTech ... - AOL

   www.aol.com/sleep-apnea-device-maker-resmed...

   On Thursday, ResMed Inc (NYSE:RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11% ...

6. Hypoglossal nerve stimulator - Wikipedia

   en.wikipedia.org/wiki/Hypoglossal_nerve_stimulator

   Certain patients with obstructive sleep apnea who are deemed eligible candidates may be offered the hypoglossal nerve stimulator as an alternative. FDA-approved hypoglossal nerve neurostimulation is considered medically reasonable and necessary for the treatment of moderate to severe obstructive sleep apnea when all of the following criteria are met: [4]

7. Vivos Therapeutics Schedules Release of Third Quarter 2024 ...

   lite.aol.com/tech/story/0022/20241113/9273434.htm

   LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today ...